GlassScriptPhysician profile
Delora A Denney
NPI 1881696862
$24,017.82
in general payments reported to CMS, 2019-2025
21 companies · $749 in 2025
The $749 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,785 · 2020: $588 · 2021: $10K · 2022: $1,275 · 2023: $5,241 · 2024: $1,186 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,720 · Food and Beverage: $3,116 · Travel and Lodging: $324 · Education: $15.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,720.00 |
| Food and Beverage | $3,115.60 |
| Travel and Lodging | $324.00 |
| Education | $15.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,786.00 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Teva Pharmaceuticals USA, INC. | $4,013.15 | 2019 | |
| Astellas Pharma US INC | $3,815.85 | 2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $2,007.27 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,168.71 | 2019-2025 | Evenity, Prolia, Repatha |
| Allergan, INC. | $1,098.97 | 2019-2021 | |
| Lilly USA, LLC | $702.21 | 2019-2025 | Zepbound, Mounjaro, Emgality |
| Pfizer INC. | $284.16 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.55 | 2019-2021 | |
| Novo Nordisk INC | $191.26 | 2020-2024 | Wegovy |
| Astellas Pharma Global Development | $134.33 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $126.74 | 2024 | |
| Novartis Pharmaceuticals Corporation | $124.11 | 2022-2024 | |
| Lundbeck LLC | $120.53 | 2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $93.97 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36.94 | 2023 | Shingrix, Boostrix, Arexvy |
| Sanofi Pasteur INC. | $33.27 | 2021-2022 | |
| Edwards Lifesciences Corporation | $29.59 | 2024 | |
| Scilex Pharmaceuticals INC. | $21.00 | 2023 | Ztlido |
| Seqirus USA INC | $17.15 | 2025 | Fluad, Flucelvax |
| Kowa Pharmaceuticals America, INC. | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delora Denney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.